Deciphera Pharmaceuticals (DCPH) News Today → The #1 Crypto That You Don’t Own… Yet (From Crypto 101 Media) (Ad) Free DCPH Stock Alerts $25.59 +0.02 (+0.08%) (As of 01:23 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 8 at 2:56 PM | marketbeat.comNew Leaf Venture Partners L.L.C. Sells 632,596 Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)New Leaf Venture Partners L.L.C. reduced its stake in shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) by 52.3% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 576,975 shares of the company's stock aJune 7 at 5:58 AM | marketbeat.com50,735 Shares in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Acquired by Campbell & CO Investment Adviser LLCCampbell & CO Investment Adviser LLC bought a new position in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) in the fourth quarter, according to its most recent filing with the SEC. The firm bought 50,735 shares of the company's stock, valued at approximately $818,000. Campbell & CO InJune 5, 2024 | marketbeat.comDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Shares Bought by Armistice Capital LLCArmistice Capital LLC raised its stake in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) by 12.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,200,000 shares of the company's stock after acJune 4, 2024 | marketbeat.comDimensional Fund Advisors LP Raises Position in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)Dimensional Fund Advisors LP raised its holdings in shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) by 6.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,561,654 shaJune 3, 2024 | businesswire.comDeciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The LancetJune 2, 2024 | americanbankingnews.comDeciphera Pharmaceuticals (NASDAQ:DCPH) Reaches New 1-Year High at $25.55May 31, 2024 | marketbeat.comDeciphera Pharmaceuticals (NASDAQ:DCPH) Sets New 52-Week High at $25.55Deciphera Pharmaceuticals (NASDAQ:DCPH) Sets New 1-Year High at $25.55May 28, 2024 | marketbeat.comBNP Paribas Financial Markets Boosts Stock Holdings in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)BNP Paribas Financial Markets boosted its stake in shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) by 118.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 77,653 shares of thMay 26, 2024 | marketbeat.comTrexquant Investment LP Takes $2.19 Million Position in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)Trexquant Investment LP acquired a new stake in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 135,994 shares of the company's stock,May 24, 2024 | marketbeat.comDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Receives Average Recommendation of "Hold" from BrokeragesDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Get Free Report) has been assigned a consensus recommendation of "Hold" from the ten ratings firms that are covering the firm, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a hold recommendation and three have gMay 22, 2024 | msn.comDeciphera Pharmaceuticals ticks higher as HSR waiting period for ONO sale expiresMay 22, 2024 | marketbeat.comJump Financial LLC Takes $522,000 Position in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)Jump Financial LLC purchased a new position in shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 32,375 shares of the company's stoMay 19, 2024 | marketbeat.comPanagora Asset Management Inc. Acquires 144,097 Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)Panagora Asset Management Inc. grew its holdings in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) by 157.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 235,845 shares of the company'sMay 16, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Deciphera Pharmaceuticals (DCPH), Atara Biotherapeutics (ATRA) and Nkarta (NKTX)May 14, 2024 | markets.businessinsider.comDeciphera Pharmaceuticals: Hold Rating Amid Acquisition and Concerns Over Qinlock SalesMay 13, 2024 | marketbeat.comDeciphera Pharmaceuticals (NASDAQ:DCPH) Sees Strong Trading VolumeDeciphera Pharmaceuticals (NASDAQ:DCPH) Sees Unusually-High Trading VolumeMay 10, 2024 | investorplace.comDCPH Stock Earnings: Deciphera Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024May 10, 2024 | marketbeat.comFisher Asset Management LLC Acquires New Position in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)Fisher Asset Management LLC acquired a new stake in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 62,372 shares of the company's stock, vMay 2, 2024 | stockhouse.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MCBC, DCPH, HTLF, TBNKMay 1, 2024 | businesswire.comDECIPHERA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Deciphera Pharmaceuticals, Inc. - DCPHMay 1, 2024 | msn.comBarclays Upgrades Deciphera Pharmaceuticals (DCPH)May 1, 2024 | marketbeat.comDeciphera Pharmaceuticals (NASDAQ:DCPH) Cut to Market Perform at Leerink PartnrsLeerink Partnrs cut Deciphera Pharmaceuticals from an "outperform" rating to a "market perform" rating in a research note on Monday.April 30, 2024 | msn.comJefferies Downgrades Deciphera Pharmaceuticals (DCPH)April 30, 2024 | marketbeat.comDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Short Interest Down 5.1% in AprilDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Get Free Report) saw a significant drop in short interest in the month of April. As of April 15th, there was short interest totalling 5,750,000 shares, a drop of 5.1% from the March 31st total of 6,060,000 shares. Approximately 11.5% of the company's shares are sold short. Based on an average daily trading volume, of 525,500 shares, the days-to-cover ratio is presently 10.9 days.April 30, 2024 | markets.businessinsider.comDeep Dive Into Deciphera Pharmaceuticals Stock: Analyst Perspectives (5 Ratings)April 30, 2024 | msn.comJonesTrading Downgrades Deciphera Pharmaceuticals (DCPH)April 30, 2024 | marketbeat.comDeciphera Pharmaceuticals (NASDAQ:DCPH) Sees Large Volume IncreaseDeciphera Pharmaceuticals (NASDAQ:DCPH) Sees Unusually-High Trading VolumeApril 30, 2024 | marketbeat.comDeciphera Pharmaceuticals (NASDAQ:DCPH) Earns "Neutral" Rating from GuggenheimGuggenheim reiterated a "neutral" rating on shares of Deciphera Pharmaceuticals in a research note on Tuesday.April 30, 2024 | marketbeat.comDeciphera Pharmaceuticals (NASDAQ:DCPH) Rating Increased to Equal Weight at BarclaysBarclays raised shares of Deciphera Pharmaceuticals from an "underweight" rating to an "equal weight" rating and raised their price target for the stock from $9.00 to $26.00 in a research report on Tuesday.April 30, 2024 | finance.yahoo.comONO Enters into a Definitive Agreement to Acquire Deciphera PharmaceuticalsApril 30, 2024 | reuters.comJapan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansionApril 29, 2024 | prnewswire.comINVESTIGATION: The M&A Class Action Firm Announces An Investigation of Deciphera Pharmaceuticals, Inc. - DCPHApril 29, 2024 | marketbeat.comDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Get Free Report) has earned an average rating of "Moderate Buy" from the six ratings firms that are currently covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and three have assigned a bApril 29, 2024 | msn.comDeciphera to be acquired by Japanese drug firm for $2.4 billionApril 29, 2024 | finance.yahoo.comUpdate: Deciphera Pharmaceuticals to Be Acquired by ONO Pharmaceutical in $2.4 Billion DealApril 29, 2024 | finance.yahoo.comDeciphera Pharmaceuticals Is Being Acquired and the Stock Soars 72%April 29, 2024 | marketbeat.comJefferies Financial Group Reaffirms Hold Rating for Deciphera Pharmaceuticals (NASDAQ:DCPH)Jefferies Financial Group restated a "hold" rating and issued a $25.60 price target (down from $26.00) on shares of Deciphera Pharmaceuticals in a research report on Monday.April 29, 2024 | investorplace.comWhy Is Deciphera Pharmaceuticals (DCPH) Stock Up 72% Today?April 29, 2024 | prnewswire.comShareholder Alert: Ademi LLP investigates whether Deciphera Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with ONO Pharmaceutical Co.April 29, 2024 | marketbeat.comDeciphera Pharmaceuticals (NASDAQ:DCPH) Reaches New 52-Week High at $25.03Deciphera Pharmaceuticals (NASDAQ:DCPH) Reaches New 12-Month High at $25.03April 29, 2024 | barrons.comDeciphera Pharmaceuticals Is Being Acquired and the Stock Soars 71%April 29, 2024 | businesswire.comDCPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Deciphera Pharmaceuticals, Inc. Is Fair to ShareholdersApril 29, 2024 | reuters.comJapan's ONO Pharmaceutical to buy Deciphera for $2.4 billionApril 29, 2024 | businesswire.comDeciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 BillionApril 29, 2024 | marketbeat.comTrading was temporarily halted for "DCPH" at 06:04 AM with a stated reason of "News pending."April 27, 2024 | nasdaq.comDCPH Makes Notable Cross Below Critical Moving AverageApril 27, 2024 | marketbeat.comAllspring Global Investments Holdings LLC Has $345,000 Stock Position in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)Allspring Global Investments Holdings LLC trimmed its position in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) by 70.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 21,382 shares of the company's stockApril 26, 2024 | seekingalpha.comDiving Into Deciphera PharmaceuticalsApril 17, 2024 | marketbeat.comDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Sees Significant Increase in Short InterestDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Get Free Report) was the target of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 6,060,000 shares, a growth of 7.3% from the March 15th total of 5,650,000 shares. Approximately 12.3% of the company's stock are short sold. Based on an average daily volume of 540,200 shares, the days-to-cover ratio is currently 11.2 days.April 9, 2024 | businesswire.comDeciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum Get Deciphera Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DCPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New trading system called MSFT, NVDA & MSFT (Ad)Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today. Just follow this link here! DCPH Media Mentions By Week DCPH Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DCPH News Sentiment▼1.130.76▲Average Medical News Sentiment DCPH News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DCPH Articles This Week▼42▲DCPH Articles Average Week Get Deciphera Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DCPH and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SNDX News Today XNCR News Today ALXO News Today MCRB News Today ROIV News Today INSM News Today ASND News Today CERE News Today LEGN News Today ITCI News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DCPH) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersTrump convicted... now what?Unexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | Sponsored[PDF Inside] Crypto's $1 Trillion 60-Day Boom + New 2024 Profit StrategyThe crypto industry is exploding and Chris Munch just released a new PDF detailing how you can potentially pro...DeFi Distribution | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | Sponsored